Pliant Therapeutics, Inc. (PLRX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.11 USD
-0.04
(-3.478%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.12 +0.01 (0.541%) ⇧ (Aug. 28, 2026, 5:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:13 a.m. EDT
The investment case here is broken by a catastrophic multi-year decline. The stock has lost 94% of its value over the last five years, with the last three years showing consecutive negative returns. This is not a temporary correction; it is a structural implosion where the market has priced out the business entirely. Fundamentals confirm the doom: negative earnings, negative free cash flow, and a return on equity of -50%. While the balance sheet shows high liquidity relative to debt, the company is burning cash aggressively with no visible path to profitability. The lack of dividends offers no cushion. On the short end, the technicals are weak, trading below key moving averages, and the statistical forecast leans slightly negative, though that is a weak signal in the face of such a steep fundamental decline. The options market is screaming 'sell' or 'hedge,' with put open interest dwarfing call interest. This is a deep value trap where the low price reflects a permanent impairment of the business model. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.033911 |
| AutoARIMA | 0.037886 |
| AutoETS | 0.037886 |
| MSTL | 0.038361 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.365 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.563 |
| Market Cap | 68,733,304 |
| Forward P/E | -0.83 |
| Beta | 1.27 |
| Website | https://pliantrx.com |
As of Aug. 22, 2026, 3:13 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is massive (2.2k contracts) compared to negligible call open interest (318 contracts), indicating a heavy hedge against further declines. While there is some call volume at the $2.50 strike, the overwhelming weight of the options chain suggests investors expect the price to remain well below current levels or drop further, with very little capital betting on a recovery to par.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3134328 |
| Address1 | 331 Oyster Point Boulevard |
| All Time High | 43.92 |
| All Time Low | 1.02 |
| Ask | 1.13 |
| Ask Size | 1 |
| Average Analyst Rating | 3.2 - Hold |
| Average Daily Volume10 Day | 467,260 |
| Average Daily Volume3 Month | 521,545 |
| Average Volume | 521,545 |
| Average Volume10Days | 467,260 |
| Beta | 1.27 |
| Bid | 1.12 |
| Bid Size | 1 |
| Book Value | 2.373 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.11 |
| Current Ratio | 9.897 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.15 |
| Day Low | 1.11 |
| Debt To Equity | 19.563 |
| Display Name | Pliant Therapeutics |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -89,866,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.675 |
| Enterprise Value | -60,624,696 |
| Eps Current Year | -1.46206 |
| Eps Forward | -1.3306 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1109 |
| Fifty Day Average Change | -0.00090003014 |
| Fifty Day Average Change Percent | -0.000810181 |
| Fifty Two Week Change Percent | -31.34328 |
| Fifty Two Week High | 1.95 |
| Fifty Two Week High Change | -0.84000003 |
| Fifty Two Week High Change Percent | -0.43076923 |
| Fifty Two Week Low | 1.02 |
| Fifty Two Week Low Change | 0.09000003 |
| Fifty Two Week Low Change Percent | 0.088235326 |
| Fifty Two Week Range | 1.02 - 1.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,591,191,000,000 |
| Float Shares | 55,033,705 |
| Forward Eps | -1.3306 |
| Forward P E | -0.8342101 |
| Free Cashflow | -42,508,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 49 |
| Fullday Change | -0.04 |
| Fullday Change Percent | -3.47826 |
| Fullday Price | 1.116 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02226 |
| Held Percent Institutions | 0.79241997 |
| Implied Shares Outstanding | 61,921,897 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Pliant Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 68,733,304 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_325980525 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -92,289,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 71,829,400 |
| Number Of Analyst Opinions | 2 |
| Open | 1.15 |
| Operating Cashflow | -70,895,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 481 6770 |
| Post Market Change | 0.006000042 |
| Post Market Change Percent | 0.54054433 |
| Post Market Price | 1.116 |
| Post Market Time | 1,787,953,603 |
| Previous Close | 1.15 |
| Price Eps Current Year | -0.7592028 |
| Price Hint | 4 |
| Price To Book | 0.46776235 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.644 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.2 |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -3.47826 |
| Regular Market Day High | 1.15 |
| Regular Market Day Low | 1.11 |
| Regular Market Day Range | 1.11 - 1.15 |
| Regular Market Open | 1.15 |
| Regular Market Previous Close | 1.15 |
| Regular Market Price | 1.11 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 233,137 |
| Return On Assets | -0.23274 |
| Return On Equity | -0.50293 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,921,897 |
| Shares Percent Shares Out | 0.044699997 |
| Shares Short | 2,768,737 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,821,841 |
| Short Name | Pliant Therapeutics, Inc. |
| Short Percent Of Float | 0.045700002 |
| Short Ratio | 5.28 |
| Source Interval | 15 |
| State | CA |
| Symbol | PLRX |
| Target High Price | 3.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 2.5 |
| Target Median Price | 2.5 |
| Total Cash | 158,100,992 |
| Total Cash Per Share | 2.553 |
| Total Debt | 28,743,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.242275 |
| Two Hundred Day Average Change | -0.13227499 |
| Two Hundred Day Average Change Percent | -0.10647802 |
| Type Disp | Equity |
| Volume | 233,137 |
| Website | https://pliantrx.com |
| Zip | 94,080 |